Table 1.
Summary of the impact of EBV on clinical outcome from published literature. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) cases were included in some studies. POS: positive effect of EBV on clinical outcome; NEG: negative effect of EBV on clinical outcome. “no” means no significant effect of EBV on clinical outcome. “No entry” means that the effect on clinical outcome was not studied in that group. * This was a meta-analysis that did not take age into account.
| Study | Population | No. of Patients | NLPHL Included | Age (Years) | Effect (No Age Split) | Children/Adolescents | Young Adults | Older Adults |
|---|---|---|---|---|---|---|---|---|
| Claviez (2005) [63] | Multinational | 842 | yes | 2–20 | NEG | |||
| Koh (2018) [64] | South Korea | 135 | no | <15 | NEG | |||
| Dinand (2007) [60] | India | 118 | yes | <15 | no | |||
| Aktas (2007) [61] | Turkey | 63 | no | Paediatric patients | no | |||
| Chabay (2008) [62] | Brazil, Argentina | 176 | yes | 0–18 | no | |||
| Engel (2000) [58] | South Africa | 36 | no | ≤14 | POS | |||
| Keegan (2005) [46] | USA | 922 | no | up to 96 | POS | no | NEG | |
| Barros (2010) [59] | Brazil | 104 | no | up to 18 | POS | |||
| Koh (2012) [53] | S Korea | 159 | yes | 4–77 | NEG | NEG | ||
| Jarrett (2005) [47] | UK | 437 | no | 16–74 | NEG | no | NEG | |
| Clarke (2001) [48] | USA | 311 | yes | 19–79 | no | NEG | ||
| Kwon (2006) [54] | Korea | 56 | yes | 6–77 | NEG | POS | ||
| Glavina-Durdov (2001) [55] | Croatia | 100 | yes | 13–84 | no | POS | ||
| Murray (1999) [56] | UK | 190 | yes | 22–49 | POS | |||
| Flavell (2003) [57] | UK | 273 | yes | ≥15 | no | POS | ||
| Stark (2002) [49] | UK | 102 | yes | ≥60 | NEG | |||
| Diepstra (2009) [50] | Netherlands | 412 | no | 7–91 | no | NEG | ||
| Wang (2021) [51] | China | 134 | yes | 5–74 | no | NEG | ||
| Enblad (1999) [65] | Sweden | 117 | yes | 11–87 | NEG | |||
| Proctor (2002) [52] | UK | 94 | no | >60 | no | |||
| Herling(2003) [66] | USA, Italy, Greece | 303 | no | adults | no | |||
| Axdorph (1999) [67] | Sweden | 95 | no | 14–77 | no | |||
| Enblad (1997) [68] | Sweden | 107 | yes | 6–87 | no | |||
| Keresztes (2006) [69] | Hungary | 109 | no | >61 | no | |||
| Krugmann (2003) [70] | Austria | 119 | no | 14–83 | POS | |||
| Naresh (2000) [71] | India | 110 | no | 4–61 | POS | |||
| Morente (1997) [72] | Spain | 140 | yes | 5–83 | POS | |||
| Montalban (2000) [73] | Spain | 110 | yes | NK | POS | |||
| Trimeche (2007) [74] | Belgium | 111 | no | 8–88 | NEG | |||
| Quijano (2004) [75] | Columbia | 67 | no | NK | POS | |||
| Myriam (2017) [76] | Tunisia | 131 | no | 4–83 | NEG | |||
| Santisteban-Espejo (2021) [77] | Spain | 88 | no | 19–82 | NEG | |||
| Elsayed (2014) [78] | Japan | 389 | no | 4–89 | NEG | |||
| Souza (2010) [79] | Brazil | 97 | no | >18 | no | |||
| Cheriyalinkal Parambil (2020) [80] | India | 189 | no | ≥15 | POS | |||
| Vestlev (1992) [81] | Denmark | 66 | no | 12.8–60.5 | no | |||
| Armstrong (1994) [82] | UK | 59 | yes | NK | no | |||
| Levy (2000) [83] | Israel | 134 | yes | 4–50+ | NEG | |||
| Vassalo (2003) [84] | Brazil | 78 | no | >15 | POS | |||
| Lee (2014) [85] | various | * | NA | NA | no |